Glenmark Pharmaceuticals has announced the launch of GLIPIQⓇ (semaglutide) in India for the management of Type 2 Diabetes Mellitus (T2DM), setting a new benchmark in affordability for GLP-1 therapy and expanding access to advanced diabetes treatment for patients.
GLIPIQⓇ is available in both vial and pre-filled pen formulations. The product has been approved by the Central Drugs Standard Control Organization (CDSCO) following a multicentre, randomised, comparative, active-controlled, open-label Phase III clinical study conducted in India, demonstrating favourable efficacy and safety outcomes in Indian patients with Type 2 diabetes.
The expected weekly cost of treatment with GLIPIQⓇ vials ranges from ₹325 to ₹440, significantly lowering the cost barrier to initiate GLP-1 therapy in India and establishing a more affordable entry point into this class of treatment. In addition to vials, GLIPIQⓇ is also available in a pre-filled pen format, offering the convenience of self-dosing for long-term therapy. Both – vial and pen – are available in strengths of 2 mg/1.5 mL, 4 mg/3 mL, and 8 mg/3 mL.
The company has also introduced a patient-centric program- ‘Sankalp’ to support therapy initiations, improve comfort with injectable treatment, and enable long-term adherence.
Commenting on the launch, Mr. Alok Malik, President and Business Head, India Formulations, Glenmark Pharmaceuticals Ltd., said, “With GLIPIQⓇ, we are setting a new benchmark in affordability for GLP-1 therapy, with weekly treatment starting at ₹325. The vial-based format enables us to offer a more affordable option while supporting clinically guided initiation and flexible dosing. Building on our experience in the GLP-1 category, including Lirafit™ (Liraglutide), and supported by our ‘Sankalp’ program, we aim to help more patients access, initiate, and continue therapy over time.”
